Therefore, antibodies directed against PD-1, such as pembrolizumab and nivolumab, or PD-L1, such as atezolizumab and durvalumab, have been used to restore T cell-mediated immunosurveillance against proliferating cancer cells [3,22,23,24,25,26,27,28,29,30]. The gene discussed is PDCD1; the disease is cancer.